Hexima is pleased to be featured in the Australian Financial Review (AFR) article which highlights the often challenging path for Australian biotechs from clinical trails to commercialisation.
CEO, Michael Aldrige, explains why he thinks Hexima is positioned well to progress HXP124 through clinical trials and why the novel charateristics and promising efficacy to date will be attractive to patients.
View the full Australian Financial Review article here → AFR Article